Supriya Lifescience Limited is a manufacturer of Active pharmaceutical ingredients (APIs). Established in the year 1987, the company mainly focuses on products related to various therapeutic segments like Anti-Histamine, Anti-allergics, Anti-Asthmatics, etc.
The company mainly focuses on developing APIs and Intermediates for both Innovators and Generic companies. Apart from India the company exports products to 86 countries including 346 distributors. The company has API business in Europe, Asia, and North America.
Supriya Lifescience Ltd manufacturing facility has received approvals from USFDA, EDQM TGA-Australia, KFDA-Korea, PMDA Japan, NMPA (previously known as SFDA)- China, Health Canada related to API products.
The company plans to raise funds accumulating up to ₹700 crores. The Supriya Lifescience IPO has a fresh issue of equity shares aggregating up to Rs. 200 Cr.
he Company has put a price band of 265 to ₹274 per equity share. The IPO closed on 20th December.
Supriya Lifescience IPO GMP
|DATE||GMP||KOSTAK||SUBJECT TO SAUDA|
The Company has come up with its IPO to funding the working capital requirements n expanding the production and distribution network.
Supriya Lifescience IPO Details
- Face Value: Rs 2 per equity share
- IPO price Range: ₹265 to ₹274 per equity share
- Issue Size: 700 Cr